PEG-IL-2v

PEG-IL-2v (RG6279) is an investigational, long-acting, PEGylated interleukin-2 (IL-2) variant developed by Roche for the treatment of solid tumors. The IL-2 variant (IL-2v) component is protein-engineered to abolish binding to the high-affinity IL-2 receptor alpha subunit (CD25), which is constitutively expressed on regulatory T cells (Tregs) and vascular endothelial cells. By eliminating CD25 binding, PEG-IL-2v avoids the preferential activation of immunosuppressive Tregs and reduces the risk of vascular leak syndrome, a major dose-limiting toxicity of wild-type IL-2 therapy. Instead, the molecule selectively activates the intermediate-affinity IL-2 receptor complex composed of the beta (CD122) and gamma (CD132) subunits, which are found on cytotoxic CD8+ T cells and natural killer (NK) cells. The addition of polyethylene glycol (PEG) chains significantly extends the systemic half-life of the cytokine, enabling a more convenient dosing schedule and sustained immune activation in the tumor microenvironment.

Other names

PEGylated IL-2 variantPEG-IL2vPEG-IL-2vPEG-IL 2v